The European Investment Bank (EIB) has signed a €150 million financing agreement with Alfasigma, a global pharmaceutical company founded in Italy with products present in over 100 markets worldwide. The agreement, announced by EIB Vice-President Gelsomina Vigliotti and Alfasigma's Chief Financial Officer Tatiana Simonelli, will support the development of breakthrough therapies in rare diseases and specialty care sectors.
Strategic Focus on Unmet Medical Needs
The EIB financing aims to support Alfasigma's R&D activities over the three-year period from 2025 to 2027, with a specific focus on new treatments in gastroenterology and hepatology, vascular medicine, and rheumatology. The funding will help accelerate the translation of scientific advances into patient-centered solutions, aiming to address unmet needs and deliver high-impact health outcomes.
The agreement will help accelerate the transformation of scientific progress into concrete solutions capable of responding to the real needs of patients, with the aim of generating high-impact results for health.
European Healthcare Innovation Strategy
The operation is part of the EIB's strategy to bolster competitiveness and innovation in the European healthcare sector and to create highly skilled jobs. "This financing confirms the EIB's commitment to promoting scientific innovation and supporting European biopharmaceutical research," said EIB Vice-President Gelsomina Vigliotti. "Investing in research, development and innovation is key to strengthening Europe's industrial competitiveness and to offering new therapeutic solutions to those currently without alternatives."
Company Growth Strategy
"We are grateful to the EIB for this agreement, which will help us to fast-track our ambitious growth strategy, particularly in expanding our footprint in rare diseases and specialty care innovations to better address the unmet needs of the patients and communities we serve," said Alfasigma Chief Financial Officer Tatiana Simonelli.
The funds will help develop and market new medicines in Alfasigma's main therapeutic areas, supporting the company's expansion in the field of rare diseases and specialty care to respond to unmet patient needs.
EIB's Broader Healthcare Investment Context
The EIB Group signed 99 operations totalling €10.98 billion in Italy in 2024, helping to unlock almost €37 billion of investment in the real economy. All projects financed by the EIB Group are in line with the Paris Climate Agreement, as pledged in their Climate Bank Roadmap. Around half of the EIB's financing within the European Union is directed towards cohesion regions, where per capita income is lower than the EU average.
